NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Patients with head and neck squamous cell carcinoma diagnosed with recurrent tumor or distant metastases usually have the worst prognosis. Chemotherapeutic options are very limited in these patients; there is a probability of drug resistance development. The researchers continue to search more effec...

Full description

Bibliographic Details
Main Authors:	A. M. Mudunov, M. N. Narimanov, D. A. Safarov
Format:	Article
Language:	Russian
Published:	ABV-press 2017-06-01
Series:	Опухоли головы и шеи
Subjects:	head and neck tumors squamous cell carcinoma pd-1 immune therapy nivolumab pembrolizumab
Online Access:	https://ogsh.abvpress.ru/jour/article/view/271

Similar Items

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

An update on head and neck squamous cell carcinoma in respect to classification and systemic therapy. Extended review
by: A. Mudunov, et al.
Published: (2018-04-01)

Immunotherapy in head and neck squamous cell carcinoma: An updated review
by: K. Parmar, et al.
Published: (2022-01-01)

Evolving role of immunotherapy in head-and-neck cancers: A systemic review
by: Raajit Chanana, et al.
Published: (2018-01-01)

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
by: Yue (Jennifer) Du, et al.
Published: (2023-09-01)

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis
by: Hsiang-Fong Kao, et al.
Published: (2022-11-01)

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
by: Byoung Chul Cho, et al.
Published: (2024-07-01)

The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma
by: A. V. Ignatova, et al.
Published: (2024-06-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Global research trends in immunotherapy for head and neck neoplasms: A scientometric study
by: Zhou Jiang, et al.
Published: (2023-04-01)

Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
by: Dongmei Ye, et al.
Published: (2024-03-01)

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Piero Giuseppe Meliante, et al.
Published: (2023-02-01)

Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
by: Kohei Okuyama, et al.
Published: (2023-05-01)

Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck
by: L. V. Bolotina, et al.
Published: (2020-07-01)

NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)
by: A. M. Mudunov
Published: (2017-11-01)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
by: Suzuki S, et al.
Published: (2022-11-01)

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma
by: Takahiro Tsujikawa, et al.
Published: (2024-07-01)

Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck
by: Allen M. Chen, et al.
Published: (2025-03-01)

Pembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practice
by: Yu. V. Alymov, et al.
Published: (2023-09-01)

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

DISEASE RECURRENCE PREDICTORS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Yuniardini S. Wimardhani, et al.
Published: (2015-06-01)

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
by: Xuefeng Wang, et al.
Published: (2025-03-01)

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Hideki Tanaka, et al.
Published: (2023-11-01)

Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas
by: Görkem Eskiizmir
Published: (2015-09-01)

Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
by: Sandra Llop, et al.
Published: (2024-11-01)

Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases
by: Aline Houessinon, et al.
Published: (2020-07-01)

Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
by: M.S. Ruban, et al.
Published: (2025-03-01)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
by: Andrea Botticelli, et al.
Published: (2020-04-01)

Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment
by: A. M. Mudunov, et al.
Published: (2020-11-01)

The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China
by: Zongyu Fan, et al.
Published: (2024-02-01)

Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study
by: Haifeng Liang, et al.
Published: (2025-02-01)

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
by: Anna Brandt, et al.
Published: (2024-02-01)

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients
by: Lu Li, et al.
Published: (2023-07-01)

Factors influencing outcomes in selective neck dissection in 661 patients with head and neck squamous cell carcinoma
by: Mattis Bertlich, et al.
Published: (2022-05-01)

Dysregulation of glucose-6-phosphate dehydrogenase in head and neck squamous cell carcinoma: Pathways, mutations, and therapeutic opportunities
by: Santhakumar Egambaram, et al.
Published: (2025-03-01)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
by: Susanne Wiegand, et al.
Published: (2023-03-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
by: David G. Pfister, et al.
Published: (2023-03-01)

Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
by: Kai Wang, et al.
Published: (2023-07-01)

PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
by: Nabulya R, et al.
Published: (2024-04-01)